.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Analyze global market entry opportunities
  • Find generic sources and suppliers

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Trandolapril - Generic Drug Details

« Back to Dashboard

What are the generic drug sources, and freedom to operate, for trandolapril?

Trandolapril is the generic ingredient in four branded drugs marketed by Watson Labs, Cipla, Epic Pharma, Invagen Pharms, Lupin, Abbvie, Aurobindo Pharma, Mylan, Corepharma, Teva Pharms, Dr Reddys Labs Ltd, and Glenmark Generics, and is included in thirteen NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

There are ten drug master file entries for trandolapril. Nine suppliers are listed for this compound.

Summary for Generic Name: trandolapril

Tradenames:4
Patents:1
Applicants:12
NDAs:13
Drug Master File Entries: see list10
Suppliers / Packagers: see list9
Bulk Api Vendors: see list41
Clinical Trials: see list3
Patent Applications: see list4,473
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:trandolapril at DailyMed

Pharmacology for Ingredient: trandolapril

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan
TRANDOLAPRIL
trandolapril
TABLET;ORAL078346-003Apr 28, 2008RXNoNo► Subscribe► Subscribe
Lupin
TRANDOLAPRIL
trandolapril
TABLET;ORAL077522-001Jun 12, 2007RXNoNo► Subscribe► Subscribe
Abbvie
TARKA
trandolapril; verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL020591-003Oct 22, 1996RXYesNo► Subscribe► Subscribe
Invagen Pharms
TRANDOLAPRIL
trandolapril
TABLET;ORAL078320-003Jun 12, 2007RXNoNo► Subscribe► Subscribe
Glenmark Generics
TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE
trandolapril; verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL079135-004Aug 30, 2010RXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: trandolapril

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie
MAVIK
trandolapril
TABLET;ORAL020528-001Apr 26, 19964,233,361► Subscribe
Abbvie
MAVIK
trandolapril
TABLET;ORAL020528-002Apr 26, 19965,744,496► Subscribe
Abbvie
MAVIK
trandolapril
TABLET;ORAL020528-003Apr 26, 19965,744,496► Subscribe
Abbvie
MAVIK
trandolapril
TABLET;ORAL020528-003Apr 26, 19964,933,361► Subscribe
Abbvie
MAVIK
trandolapril
TABLET;ORAL020528-001Apr 26, 19964,933,361► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc